What is the share price of Medicamen Biotech Ltd (MEDICAMEQ) today?
The share price of MEDICAMEQ as on 11th July 2025 is ₹391.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Medicamen Biotech Ltd (MEDICAMEQ) share?
The past returns of Medicamen Biotech Ltd (MEDICAMEQ) share are- Past 1 week: -4.77%
- Past 1 month: -8.13%
- Past 3 months: -20.52%
- Past 6 months: -17.30%
- Past 1 year: -16.56%
- Past 3 years: -43.29%
- Past 5 years: -29.04%
What are the peers or stocks similar to Medicamen Biotech Ltd (MEDICAMEQ)?
The peers or stocks similar to Medicamen Biotech Ltd (MEDICAMEQ) include:What is the dividend yield % of Medicamen Biotech Ltd (MEDICAMEQ) share?
The current dividend yield of Medicamen Biotech Ltd (MEDICAMEQ) is 0.24.What is the market cap of Medicamen Biotech Ltd (MEDICAMEQ) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Medicamen Biotech Ltd (MEDICAMEQ) is ₹531.26 Cr as of 11th July 2025.What is the 52 week high and low of Medicamen Biotech Ltd (MEDICAMEQ) share?
The 52-week high of Medicamen Biotech Ltd (MEDICAMEQ) is ₹630 and the 52-week low is ₹375.05.What is the PE and PB ratio of Medicamen Biotech Ltd (MEDICAMEQ) stock?
The P/E (price-to-earnings) ratio of Medicamen Biotech Ltd (MEDICAMEQ) is 74.82. The P/B (price-to-book) ratio is 2.57.Which sector does Medicamen Biotech Ltd (MEDICAMEQ) belong to?
Medicamen Biotech Ltd (MEDICAMEQ) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Medicamen Biotech Ltd (MEDICAMEQ) shares?
You can directly buy Medicamen Biotech Ltd (MEDICAMEQ) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Medicamen Biotech Ltd
MEDICAMEQ Share Price
391.700.32% (+1.25)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
MEDICAMEQ Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
MEDICAMEQ Performance & Key Metrics
MEDICAMEQ Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 61.35 | 2.57 | 0.24% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.72 | 6.42 | 0.79% |
MEDICAMEQ Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
MEDICAMEQ Company Profile
MEDICAMEN Biotech is engaged in manufacturing of pharmaceutical formulations.
SUNPHARMA
PE Ratio
36.71
36.71
1Y Return
5.71%
5.71%
Buy Reco %
87.10
87.10
CIPLA
PE Ratio
22.75
22.75
1Y Return
1.39%
1.39%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
58.69
58.69
1Y Return
12.03%
12.03%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
53.44
53.44
1Y Return
21.78%
21.78%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.46
18.46
1Y Return
4.87%
4.87%
Buy Reco %
50.00
50.00
MEDICAMEQ Forecast
MEDICAMEQ Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
MEDICAMEQ
MEDICAMEQ
Income
Balance Sheet
Cash Flow
Annual Normal View
MEDICAMEQ Income Statement
MEDICAMEQ Income Statement
Annual Normal View
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 126.26 | 127.44 | 113.47 | 117.17 | 143.33 | 181.64 | 168.79 | 168.78 | ||||||||
Raw Materials | 81.95 | 80.45 | 68.42 | 55.69 | 81.80 | 104.70 | 148.69 | 148.69 | ||||||||
| Power & Fuel Cost | 2.11 | 2.90 | 2.68 | 5.86 | 5.67 | 7.14 | ||||||||||
| Employee Cost | 8.09 | 9.52 | 9.00 | 14.50 | 20.15 | 29.07 | ||||||||||
| Selling & Administrative Expenses | 5.30 | 5.16 | 4.14 | 7.79 | 7.90 | 14.95 | ||||||||||
| Operating & Other expenses | 7.69 | 8.00 | 8.80 | 7.51 | 1.00 | -0.07 | ||||||||||
EBITDA | 21.12 | 21.41 | 20.43 | 25.82 | 26.81 | 25.85 | 20.10 | 20.09 | ||||||||
| Depreciation/Amortization | 2.21 | 2.50 | 2.52 | 5.77 | 6.37 | 7.09 | 7.07 | 7.07 | ||||||||
| PBIT | 18.91 | 18.91 | 17.91 | 20.05 | 20.44 | 18.76 | 13.03 | 13.02 | ||||||||
| Interest & Other Items | 1.38 | 0.93 | 1.51 | 1.94 | 3.39 | 5.67 | 3.16 | 3.16 | ||||||||
| PBT | 17.53 | 17.98 | 16.40 | 18.11 | 17.05 | 13.09 | 9.87 | 9.86 | ||||||||
| Taxes & Other Items | 5.50 | 4.69 | 4.27 | 3.20 | 2.20 | 2.14 | 2.77 | 1.20 | ||||||||
| Net Income | 12.03 | 13.29 | 12.13 | 14.91 | 14.85 | 10.95 | 7.10 | 8.66 | ||||||||
| EPS | 10.28 | 11.11 | 9.93 | 12.20 | 11.94 | 8.63 | 5.16 | 6.81 | ||||||||
| DPS | 1.00 | 0.50 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Payout ratio | 0.10 | 0.04 | 0.10 | 0.08 | 0.08 | 0.12 | 0.19 | 0.15 |
MEDICAMEQ Company Updates
MEDICAMEQ Stock Peers
MEDICAMEQ Past Performance & Peer Comparison
MEDICAMEQ Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Medicamen Biotech Ltd | 74.82 | 2.57 | 0.24% |
| Sun Pharmaceutical Industries Ltd | 36.71 | 5.53 | 0.96% |
| Cipla Ltd | 22.75 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 58.69 | 14.78 | 0.18% |
MEDICAMEQ Stock Price Comparison
Compare MEDICAMEQ with any stock or ETFCompare MEDICAMEQ with any stock or ETF
MEDICAMEQ
MEDICAMEQ Holdings
MEDICAMEQ Shareholdings
MEDICAMEQ Promoter Holdings Trend
MEDICAMEQ Promoter Holdings Trend
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
MEDICAMEQ Institutional Holdings Trend
MEDICAMEQ Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.29%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
MEDICAMEQ Shareholding Pattern
MEDICAMEQ Shareholding Pattern
MEDICAMEQ Shareholding History
MEDICAMEQ Shareholding History
Foreign Institutions
smallcases containing MEDICAMEQ stock
smallcases containing MEDICAMEQ stock
Looks like this stock is not in any smallcase yet.
MEDICAMEQ Events
MEDICAMEQ Events
MEDICAMEQ Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
MEDICAMEQ has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.24%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.39 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
MEDICAMEQ Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
MEDICAMEQ has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.24%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.39 every year
MEDICAMEQ Upcoming Dividends
MEDICAMEQ Upcoming Dividends
No upcoming dividends are available
MEDICAMEQ Past Dividends
MEDICAMEQ Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2024
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 19, 2024
Cash Dividend
Ex DateEx DateSep 20, 2023
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 20, 2023
Cash Dividend
Ex DateEx DateSep 19, 2022
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 19, 2022
Cash Dividend
Ex DateEx DateSep 16, 2021
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 16, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 17, 2020
MEDICAMEQ Stock News & Opinions
MEDICAMEQ Stock News & Opinions
Articles & Videos
Spotlight
Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection
The ANDA pertains to Bortezomib for Injection, 3.5 mg single-dose vial. The USFDA has determined that the product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Velcade for Injection, 3.5 mg/vial, marketed by Takeda Pharmaceuticals U.S.A. Inc. (NDA-021602). This milestone marks a significant step forward in the company's strategy to enter regulated markets. The Bortezomib API was developed in-house through the company's R&D efforts and manufactured at Shivalik Rasayan, which holds USDMF 036171. The achievement underscores Medicamen's capabilities in successfully developing and commercializing products using its own R&D and API manufacturing infrastructure, built over the past few years. It also highlights the company's strong commitment to stringent quality standards, robust regulatory compliance, and adherence to Current Good Manufacturing Practices (cGMP). Medicamen reaffirmed its dedication to maintaining the integrity of its products and systems as it continues to expand its footprint in the U.S. market. Medicamen Biotech is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations. The company's consolidated net profit rose 13.6% to Rs 2.42 crore in Q4 FY25, despite a 37.4% decline in revenue from operations to Rs 29.61 crore compared to the year-ago period. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Medicamen Biotech recommends final dividend
Medicamen Biotech announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Medicamen Biotech consolidated net profit rises 13.62% in the March 2025 quarter
Net profit of Medicamen Biotech rose 13.62% to Rs 2.42 crore in the quarter ended March 2025 as against Rs 2.13 crore during the previous quarter ended March 2024. Sales declined 37.43% to Rs 29.61 crore in the quarter ended March 2025 as against Rs 47.32 crore during the previous quarter ended March 2024. For the full year,net profit declined 34.95% to Rs 7.11 crore in the year ended March 2025 as against Rs 10.93 crore during the previous year ended March 2024. Sales declined 9.35% to Rs 162.55 crore in the year ended March 2025 as against Rs 179.31 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales29.6147.32 -37 162.55179.31 -9 OPM %-5.4412.15 -8.5312.40 - PBDT2.974.43 -33 16.9520.17 -16 PBT2.492.66 -6 9.8813.08 -24 NP2.422.13 14 7.1110.93 -35 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Medicamen Biotech to hold board meeting
Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Medicamen Biotech to convene EGM
Medicamen Biotech announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 26 March 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Medicamen Biotech announces board meeting date
Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 26 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Medicamen Biotech consolidated net profit rises 44.58% in the December 2024 quarter
Net profit of Medicamen Biotech rose 44.58% to Rs 3.47 crore in the quarter ended December 2024 as against Rs 2.40 crore during the previous quarter ended December 2023. Sales declined 2.92% to Rs 45.14 crore in the quarter ended December 2024 as against Rs 46.50 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales45.1446.50 -3 OPM %14.8610.52 - PBDT6.095.08 20 PBT3.883.27 19 NP3.472.40 45 Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Medicamen Biotech standalone net profit declines 9.03% in the December 2024 quarter
Net profit of Medicamen Biotech declined 9.03% to Rs 2.52 crore in the quarter ended December 2024 as against Rs 2.77 crore during the previous quarter ended December 2023. Sales declined 6.92% to Rs 41.14 crore in the quarter ended December 2024 as against Rs 44.20 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales41.1444.20 -7 OPM %15.1712.67 - PBDT5.655.78 -2 PBT3.484.02 -13 NP2.522.77 -9 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Medicamen Biotech to declare Quarterly Results
Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Medicamen Biotech consolidated net profit declines 3.31% in the September 2024 quarter
Net profit of Medicamen Biotech declined 3.31% to Rs 1.46 crore in the quarter ended September 2024 as against Rs 1.51 crore during the previous quarter ended September 2023. Sales rose 2.76% to Rs 44.74 crore in the quarter ended September 2024 as against Rs 43.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales44.7443.54 3 OPM %11.8710.66 - PBDT4.564.29 6 PBT1.962.46 -20 NP1.461.51 -3 Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.78%, vs industry avg of 10%
Over the last 5 years, market share decreased from 0.05% to 0.04%
Over the last 5 years, net income has grown at a yearly rate of -11.78%, vs industry avg of 19.96%